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Adverse eventBackground: As of 2014, routine vaccination strategies in Japan have included the varicella vaccine. Given
the widespread use of the vaccine, it is important to investigate the safety profile of the vaccine strain,
Oka/Biken varicella, in Japanese patients.
Methods: Reports of adverse events associated with varicella vaccination between 2005 and 2015 were
retrospectively reviewed. Virological analysis was performed on clinical specimens collected from some
of the reported cases to determine whether the etiological agent was the wild-type or Oka vaccine–
strains.
Results: There were 351 reports (3.71/100,000 doses) of adverse events during the observation period.
Among the 351 reports, there were 88 reports (0.93/100,000 doses) of varicella-like and 66 reports
(0.70/100,000 doses) of zoster-like skin rashes. The wild-type strain induced varicella-like skin rashes
earlier than the Oka vaccine strain. The Oka vaccine strain induced zoster-like skin rashes in younger
patients compared to the wild-type strain. The onset of zoster-like skin rashes after vaccination was ear-
lier in patients vaccinated with the Oka vaccine–type strain.
Conclusion: The Oka/Biken vaccine is generally safe and well tolerated in Japan. Clinical aspects of
adverse reactions caused by the Oka vaccine strain were consistent with previous reports from the
United States and Europe.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
The live attenuated varicella vaccine derived from the Oka
strain was developed by Takahashi in 1974 [1]. Initially, varicella
vaccine was developed for preventing fatal varicella in immuno-
compromised children such as patients with leukemia [2–4] and
nephrotic syndrome [1]. The prophylactic use of the varicella vac-
cine was approved in Japan in 1986. This vaccine contains a mini-
mum of 1000 plaque-forming units of Oka/Biken varicella virus in
0.5-mL dose when reconstituted by 0.7-mL sterile preparation.
Before reconstitution, this vaccine is stored under 5 C. It has been
demonstrated that cold chain of vaccine products was well main-
tained in Japan. In healthy Japanese children, a single dose of the
varicella vaccine induced strong immunity that persisted for
20 years [5]. Previous studies conducted in the United Statesdemonstrated the efficacy of the varicella vaccine following the
adoption of the universal immunization against varicella in 1996
[6–10]. Although the varicella vaccine was developed almost four
decades ago in Japan, the vaccine has been administered on a vol-
untary basis until 2014. Therefore, in Japan, vaccine coverage has
been insufficient to control the epidemic of varicella as evidenced
by a consistent seasonal epidemiological pattern of varicella [11].
In Japan, varicella vaccination has been approved for children over
1 year old and adults without past history of varicella. Varicella
vaccine has been generally administered on upper arm in Japan
to date. Indeed, recently, as many vaccines have been recom-
mended as routine immunization as similar to United States and
European countries, administration of varicella vaccine on leg will
be common in future. As co-administration of the vaccine with
measles and rubella vaccine has been approved, these two vaccines
have been administered simultaneously, indeed precise number of
subjects with co-administration of the two vaccine is unclear.
The two commercially available varicella vaccines were derived
from the original Biken Oka strain (Oka/Biken): (Oka/Merck: VAR-
IVAX and Oka/RIT: VARILRIX). In postmarketing studies to evaluate
the safety profile of these vaccines, both vaccines were safe and
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[12–16]. Following the adoption of the universal immunization of
the Oka/Biken varicella vaccine in Japan, number of children
received with varicella vaccine will increase immediately.
Therefore, it is important to determine the safety profile of the
Oka/Biken varicella vaccine in Japan. In this study, we examined
reports of adverse events between 2005 and 2015.2. Methods
2.1. Postmarketing surveillance
The postmarketing reporting system for adverse reactions is a
passive, spontaneous, voluntary reporting system from health care
professionals and consumers to Biken. All reported adverse events
were collected in a database. In this study, we analyzed all adverse
events after varicella vaccination that reported from January 1,
2005 to June 30, 2015. The database contained information about
vaccine lot, vaccination date, interval between vaccination and
onset of the skin rash, site of skin rash (in cases with herpes zos-
ter), clinical course and outcome, underlying diseases, and demo-
graphic information. In vaccine recipients who developed
varicella- or zoster-like skin eruptions, physicians ordered virolog-
ical tests on clinical specimens, such as crusts and vesicular fluid,
to differentiate between the wild-type and Oka vaccine strains.2.2. Case definitions
Varicella vaccine–associated skin rash were categorized as
either varicella-like skin rash occurred within 42 days after vacci-
nation or zoster-like skin rash after vaccination. Skin eruptions that
were reported as ‘‘zoster” or ‘‘zoster-like” skin rashes were defined
as zoster-like skin rashes.Table 1
Incidence of varicella-like skin rash and zoster-like skin rash after vaccination.
Number
of reports
Incidenceb
(/100,000 doses)
All reported adverse events 351 3.71
-Cannot rule out the relationship with
immunization
252 2.66
Skin eruptionsa 244 2.58
Skin eruptions (except varicella-like and
herpes zoster like eruptions)
69 0.73
-Cannot rule out the relationship with
immunization
60 0.63
Varicella-like 109 1.15
Occurred within 42 days 88 0.93
Vaccine strain 16 0.17
Wild type strain 15 0.16
VZV-negative 9 0.10
Not analyzed 48 0.51
Herpes zoster-like 66 0.70
Vaccine strain 10 0.11
Wild type strain 25 0.26
VZV-negative 13 0.14
Not analyzed 18 0.19
a ‘‘Skin eruptions” include varicella-like and herpes zoster-like skin eruptions,
asthma, hives, erythema multiforme, redness and so on (except injection site
reaction).
b Incidence was calculated events number against vaccine products, 9,467,000.2.3. Virological analysis
Clinical specimens that were transferred to Biken were sub-
jected to molecular epidemiological analyses. Total DNA was
extracted from the specimens using the DNeasy Tissue Kit (QIA-
GEN, Hilden, Germany). Two methods were performed to differen-
tiate between the Oka vaccine and wild-type strains. (1) Prior to
2006, restriction enzyme fragment length polymorphism (RFLP)
analysis of gene 62 was performed. A fragment of gene 62 was
amplified by PCR and the PCR product was digested with the
restriction enzymes BssHII and NaeI. The digested products
resolved on a 4% agarose gel containing ethidium bromide [17].
(2) After 2006, SNPs analysis of gene 62 using allelic discrimination
(AD) real-time PCR was carried out [18]. Real-time PCR was per-
formed with two primer sets for DNA fragments containing SNPs
position 107,136 (forward primer, 50-GTA AAC GAT CAT CCG GTG
GAC A-30; reverse primer, 50-CGG TCA CCC TTC TCC AAC AAC-30)
and position 107,252 (forward primer, 50-ACT GGA GCC CGT TGC
CTC-30; reverse primer, 50-TCC TAC AGA GTC TCC GCA GAG C-30).
Four TaqMan MGB probes were used for differentiation of the
Oka vaccine strain (probe for position 107,136, 50-VIC-ACA GAA
AGA GAG CGC GC-MGB-30; position 107,252, 50-VIC-TTG CCG
GCA TGG C-MGB-30) and the wild-type strain (probe for position
107,136, 50-FAM-CAC AGA AAG AGA GCG TGC-MGB-30; position
107,252, 50-FAM-TTG CCA GCA TGG C-MGB-30). Clinical specimens
that tested positive for the Oka vaccine strain using either method
(1) or (2) were further subjected to direct sequencing of gene 62
[17].3. Results
From 2005 to 2015, Biken produced 9.47 million vials of the live
attenuated varicella vaccine (Oka/Biken). There were 351 reports
(3.71/100,000 doses) of the adverse events during the observation
period. Of the 351 reports of adverse events, there were 88 reports
(0.93/100,000 doses) of varicella-like skin rashes and 66 reports
(0.70/100,000 doses) of zoster-like skin rashes (Table 1). Virologi-
cal analyses of clinical specimens from 40 of the 88 reports of
varicella-like skin rashes detected the Oka vaccine strain in 16
reported cases (0.17/100,000 doses) and the wild-type strain in
15 reported cases (0.16/100,000 doses). Meanwhile, virological
analyses of clinical specimens from 48 of the 66 reports of
zoster-like skin rash detected the Oka vaccine strain in 10 reported
cases (0.11/100,000 doses) and the wild-type strain in 25 reported
cases (0.26/100,000 doses).3.1. Varicella-like skin rash within 42 days after vaccination
Clinical characteristics were compared between the cases with
varicella-like skin rash caused by the Oka vaccine strain (n = 16)
and those caused by the wild-type strain (n = 15) (Table 2). The
wild-type strain induced a skin rash by a median of 12 days (range
0–16 days) after vaccination, which was shorter than that of the
Oka vaccine strain (median of 25 days, range 14–42 days). The fre-
quency of underlying diseases in the vaccine recipients was higher
in patients of the Oka vaccine strain (13 of the 16 cases had under-
lying diseases) compared to patients of the wild-type strain (2 of
the 15 cases had underlying diseases).
Clinical information for the six severe cases caused by the Oka
vaccine strain is summarized in Table 3. Four of the six cases were
clearly immunocompromised, including kidney transplant recipi-
ents and patients treated with immunosuppressive drugs. One of
the four patients who recovered, severe neurological impairments
were detected. Two of the six cases were fatal (Table 4); one of the
two cases was kidney transplant recipient treated with several
immunosuppressive drugs, and another case had severe neurolog-
ical impairments without immunosuppressive treatment. These
two fatal cases were confirmed as severe VZV infection caused
Table 2
Comparison of clinical characteristics between the patients with varicella-like skin
rash within 42 days after vaccination caused by Oka-vaccine strain and those caused
by wild-type.
Variable Vaccine
type
Wild type
Numbers of reports 16 15
Age (median; range) 3 (1–40) 1.5 (1–48)
Gender (female/male) 1 (8/8) 0.875 (7/8)
Days between onset of skin rash and
vaccination (median; range)
25 (14–42) 12 (0–16)
Severity (non-severe/severe) 10/6 13/2
Outcome (recover/sequelae/fatal/unknown) 13/0/2/1 12/0/0/3
Underlying diseases (yes/no) 13/3 2/13
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sis. Although the patients were received intensive treatments
including acyclovir administration soon after the onset of the dis-
eases, the treatments were unsuccessful.
3.2. Zoster-like skin rash
Clinical characteristics were compared between the cases with
zoster-like skin rashes caused by the Oka vaccine strain (n = 10)
and those caused by the wild-type strain (n = 25) (Table 5). The
median age of the cases with the Oka vaccine–type strain (median
age of 1 year old) was lower than the wild-type strain (median age
of 9.5). The onset of zoster-like skin rashes after vaccination was
earlier in cases with the Oka vaccine–type strain (median of
167 days) compared to cases with the wild-type strain (median
of 2506 days). Although half of the cases with Oka vaccine
strain–related zoster-like skin rashes were defined as severe cases,
all of these cases were completely recovered. In cases of either the
Oka vaccine–type or wild-type strains, some of the zoster-like skin
rashes were associated with underlying diseases.
As shown in Table 6, various dermatomes were involved in the
patients regardless to the causative strains. Although Oka vaccine
strain DNA was detected in the five skin rashes located in the vac-
cination sites, no wild-type strain DNA was detected in the clinical
samples collected from the dermatome.
4. Discussion
Postmarketing surveillance is conducted to analyze large num-
bers of vaccine recipients for the detection of rare adverse reaction.
However, a major limitation of postmarketing surveillance is the
reliance on voluntary reporting by healthcare professionals and
consumers. In some instances, adverse events may be underre-
ported or go unreported all together. Since the introduction of
universal immunization against varicella using the Oka/Merck vac-
cine in the United States and Europe, several postmarketing
surveillances in these countries have been conducted [12,15]. TheTable 3
Summary of severe cases of Oka vaccine-strain associated varicella-like skin rash occurred
Case No. Vaccination year Onset (day) Outco
1 2012 12a Fatal
2 2013 42 Recov
3 2013 25 Recov
4 2013 23 Recov
5 2014 25 Fatal
6 2015 20 Recov
a 12 days after from secondary vaccination, which mean 45 days after from first vacciOka/Merck varicella vaccine was generally well tolerated and the
most frequent adverse reaction was skin rashes. Despite the devel-
opment of the Oka vaccine strain by Takahashi in Japan in 1974 [1],
to date there have been no reports of postmarketing surveillance
data because the varicella vaccine was a voluntary vaccination
until 2014. Although breakthrough varicella could be analyzed
using the same database used in this current study, analysis of
breakthrough varicella is difficult because the numbers of break-
through varicella cases remain high in Japan. Therefore, in this
study, we analyzed reports of varicella-like skin rashes within
42 days after vaccination and zoster-like skin rashes.
The incidence of reported adverse events in this study is
approximately one-tenth of those in the previous postmarketing
reports of the Oka/Merck vaccine [12,15]. Although the precise
explanation for this low incidence of adverse events in our study
is difficult to assert, some key differences may include our report-
ing system or the racial make-up of the patients.
Previous postmarketing surveillance data revealed that
varicella-like skin rashes within 2 weeks after vaccination were
more commonly associated with the wild-type strain [12]. The pre-
sent data also demonstrated that the interval between vaccination
and the appearance of the skin rash was shorter in patients with
the wild-type strain (median of 12 days) than those with the Oka
vaccine strain (median of 25 days). It is noteworthy that the
wild-type strain was rarely detected beyond two weeks after vac-
cination. Moreover, the rate of underlying diseases was higher in
cases of skin rashes caused by the Oka vaccine strain than those
caused by the wild-type strain, suggesting that patients with
underlying disease may be at high risk for skin rashes caused by
varicella vaccine. Of the six severe cases, including two fatal cases,
varicella-like skin rashes were caused by the Oka vaccine strain
(Tables 3 and 4). Similar to previous studies [12,15], most of the
patients were immunocompromised. Based on the clinical research
that evaluated the safety and efficacy of the Oka/Biken varicella
vaccine, the criteria for administration of the vaccine in acute lym-
phoblastic leukemia and nephrotic syndrome treated with steroid
were defined [2]. Several severe adverse reactions, including fatal
outcomes, have been demonstrated in acquired [19,20] and con-
genital immunosuppressed patients [21–24]. Similar findings were
reported in this current study suggesting that the varicella vaccine
should be carefully administered to immunocompromised
patients, as well as patients with severe neurological deficit includ-
ing cerebral paralysis may be high risk for varicella vaccine.
Although similar cases were previously reported based on post
licensure safety surveillance in the United States [14], further
detailed analysis is required to determine whether those patients
are high risk. In the congenital immunodeficiency patients, it was
difficult to predict most of the severe or fatal varicella cases due
to the Oka vaccine strain before vaccination [21–24]. Thus, health-
care professionals should carefully review patient medical records
to identify potential factors that may lead to complications.
Although varicella vaccine was initially developed for protection
of immunocompromised children [2–4], effective antiviral drugswithin 42 days after vaccination.
me Immunocompromised Underlying diseases
Yes Kidney transplant
ered Yes Kidney transplant
ered Possible Hypoxic encephalopathy
ered Yes Nephrotic syndrome
Possible Cerebral palsy
ered Yes Hepatoblastoma
nation. All other cases received 1 dose of varicella vaccine.
Table 4
Summary of the two fatal cases after varicella vaccination.
Case Age
(yrs)
Gender Underlying condition or disease Immunosuppressive
drugs
Interval between vaccination and disease onset/
and death (days)
Cause of death
1 40 Male Renal transplantation due to chronic RF MMF, CyA, mPSL 45 (after 1st shot)/173 (after 1st shot) Disseminated
varicellaa
12 (after 2nd shot) DIC
2 2 Female CP due to neonatal asphyxia receiving
mechanical ventilation
N/A 25/36 Varicellaa
DIC
SIRS
RF; renal failure, DIC; disseminated intravascular coagulopathy, CP; cerebral paralysis, SIRS; systemic inflammatory response syndrome, MMF; Mycophenolate mofetil, CyA;
cyclosporine, mPSL; methyl prednisolone.
a Both cases were confirmed with Oka-vaccine strain infection by using SNPs analysis and direct sequencing of gene 62.
Table 5
Comparison of clinical characteristics between the patients with zoster-like skin rash
caused by Oka-vaccine strain and those caused by wild-type strain.
Variable Vaccine type Wild type
Numbers of reports 10 25
Age (median; range) 1 (1–4) 9.5 (1–72)
Gender (female/male) 1.0 (5/5) 1.8 (16/9)
Days between onset of skin rash and
vaccination (median; range)
167 (11–
855)
2506 (10–
5110)
Severity (non-severe/severe) 5/5 12/13
Outcome (recover/sequelae/fatal/
unknown)
9/0/0/1 21/0/0/4
Underlying diseases (yes/no) 3/7 4/21
Table 6
Regions of zoster-like skin rash; comparison between Oka-vaccine strain and wild
type strain.
Regions Vaccine type
(10 cases)
Wild type
(25 cases)
Site of the vaccination
(upper arm)
5 0
Face 1 6
Ear 0 4
Ocular 0 1
Neck 2 4
Anterior chest 2 2
Back 5 2
Abdomen 1 2
Lumber 1 2
Buttock 1 2
Genital 1 1
Lower extremity 0 0
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administer the vaccine carefully to immunocompromised host to
avoid severe adverse reaction.
This study demonstrated that zoster-like skin rashes caused by
the Oka vaccine strain occurred in younger individuals compared
to skin rashes caused by the wild-type strain. The interval between
vaccination and the onset of zoster-like skin rashes was shorter in
the cases caused by the Oka vaccine strain than those caused by
the wild-type strain. These two findings are consistent with previ-
ous postmarketing studies [12,15]. In the previous postmarketing
surveillances in the United States and Europe [12,15,16], the vac-
cine strain was frequently detected in patients with zoster-like
skin rashes after vaccination. In contrast to those studies, our study
detected more cases with zoster-like skin rashes with the wild-
type strain than the Oka vaccine strain. The differences between
our data and previous reports may be related to differences
between the surveillance systems as well as distinct properties of
the prevalence of varicella virus in the United States and Europe
compared to Japan. Taken together, these data indicate that theOka vaccine strain can be reactivated even in immunocompetent
hosts resulting in zoster. In recent studies, however, the incidence
of zoster was significantly lower in vaccine recipients than patients
with natural varicella [25–27]. Therefore, universal immunization
with the varicella vaccine is an appropriate strategy for controlling
both varicella and zoster.
As similar to previous studies [12,15], all of zoster-like skin
rashes at the administration site were caused by the Oka vaccine
strain. However, it is difficult to identify the causative strain based
on the clinical symptoms of the zoster-like skin rash because the
Oka vaccine strain was detected in the various dermatomes of
the zoster-like skin rashes. It has been demonstrated that the reac-
tivation of the wild-type strain can cause a severe form of zoster in
vaccine recipients without a history of natural varicella [28], which
may be caused by subclinical wild-type varicella infection sug-
gested by Hammershiag et al. [29]. Therefore, if a physician
observes zoster-like skin rashes in vaccine recipients, they should
distinguish between the Oka vaccine type and wild-type strains
to evaluate vaccine safety. Laboratory testing system for differenti-
ation between Oka vaccine strain and wild-type strain has been
managed by Merck and Columbia University in New York. In Japan,
it is necessary to develop similar molecular epidemiological mon-
itoring system to evaluate vaccine safety in future.References
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